Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Midi Health vs Willow

Midi Health
Graded #413

Lower grade

vs+1.8000000000000043
Willow
Graded #377

Higher grade

The verdict

Willow takes it — 58.2/100 to 56.4/100, but only just.

Willow grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth provider offering compounded GLP-1 medications in both tablet and injectable formats. Midi Health is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMidi Health +9
45
36
Dose & formulationWillow +35
40
75
Clinical oversightMidi Health +7
78
71
Labs & monitoringEven
52
52
FulfillmentMidi Health +13
78
65
Contract termsEven
55
55
Midi Health · left barWillow · right bar

The numbers

MetricMidi HealthWillow
WeighScore56.4/10058.2/100
GradeCC
Scorecard rank#413#377
SemaglutideNot disclosed$299/mo (starting dose, compounded)
TirzepatideNot disclosed$399/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Midi Health

Graded #413 · C

Strengths

  • Available in all 50 states
  • Accepts commercial insurance — a differentiator vs cash-pay-only GLP-1 telehealth
  • Menopause + metabolic-health focus suits women where GLP-1 efficacy and weight regulation overlap most
  • Transparent self-pay visit fees ($250 initial, $150 follow-up); GLP-1 can also be billed through commercial insurance (copay + deductible)

Where it loses points

  • Does not accept Medicare, Medicaid, or Medi-Cal
  • GLP-1 is prescribed at clinician discretion within a menopause plan, not guaranteed at intake
  • Menopause-focused — not the right fit for men or younger women whose main goal is weight loss
Willow

Graded #377 · C

Strengths

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard